CMS reconsiders a recent Medicare premium increase after restricting coverage for a controversial new drug.
Scholar argues that reducing pricing for prescription drugs may increase innovation.
Scholars examine the effectiveness of the contentious 340B Drug Pricing Program.
Experts consider how regulators can make drugs affordable without hindering research and development.
A federal task force proposes regulatory solutions to mitigate drug shortages.
The court ruling striking down the Affordable Care Act may get in the way of making drugs affordable.